LONDON & WILMINGTON, N.C.--(BUSINESS WIRE)--
Chiltern, a leading, global contract research organization, has been recognized for its excellence in clinical research by Life Science Leader’s 2016 CRO Leaderships Awards. For the fifth straight year, Chiltern was honored in all five core categories: Capabilities, Compatibility, Expertise, Quality and Reliability.
“We are proud to be recognized again by our peers as one of the top CROs in the industry,” said Jim Esinhart, Ph.D., Chiltern CEO. “Chiltern is the only CRO to be awarded in all five overall categories five years in a row. This is a testament to our commitment to building strong collaborative partnerships and striving for clinical excellence. We hope our continued accreditation for top-level performance provides our clients with a high level of confidence going forward.”
The CRO Leadership Awards are presented annually by Life Science Leader, with winners chosen based on research conducted by Industry Standard Research. The results are based on the evaluation of 65 CROs for 27 different performance metrics. Compared to other awards that are based on subjective voting processes, the CRO Leadership Awards ensures that quality ratings come from companies that have worked with the CRO within the last 18 months and that results are backed by experiential data.
In addition to the five overall awards, Chiltern received six additional awards for outstanding service in the Small Pharma and Big Pharma categories.
About Chiltern:
Chiltern is the leading, global mid-sized contract research organization that listens to client needs to deliver customized clinical development solutions. Chiltern’s team of more than 4,000 works across 47 countries to provide comprehensive, yet flexible and responsive, services, with specialties in Clinical Development, Oncology, Device & Diagnostics, Data, Analytics & Evaluation and Strategic Service Provision. Visit Chiltern.com to learn more about solutions that are Designed Around You®.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160407006085/en/
